A Multinational, Multicenter, Randomized, Double-Blind, Parallel Group, Active Controlled, Comparative Trial, to Assess the Endometrial Histological Profile Following Treatment With Tibolone (Org OD14) Versus Conjugated Estrogen (CE) Plus Medroxyprogesterone Acetate (MPA) in Postmenopausal Women

Trial Profile

A Multinational, Multicenter, Randomized, Double-Blind, Parallel Group, Active Controlled, Comparative Trial, to Assess the Endometrial Histological Profile Following Treatment With Tibolone (Org OD14) Versus Conjugated Estrogen (CE) Plus Medroxyprogesterone Acetate (MPA) in Postmenopausal Women

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Tibolone (Primary) ; Conjugated estrogens/medroxyprogesterone
  • Indications Menopausal syndrome; Menopause; Postmenopausal osteoporosis
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms THEBES
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 07 Oct 2009 Actual end date (Jul 2005) added as reported by ClinicalTrials.gov.
    • 16 Sep 2008 Added ID, official title, endpoints, start and end dates, from clincialtrials.gov record.
    • 15 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top